Ayano Ishii

Impact of overactive bladder and lower urinary tract symptoms on sexual health in Japanese women

Introduction and hypothesisThis study aims to assess whether lower urinary tract symptoms (LUTS) affect sexual function in Japanese females.MethodsA multi-component questionnaire was mailed to 576 female hospital workers. It contained the Female Sexual Function Index (FSFI) and a self-administered questionnaire pertaining to LUTS.ResultsOf the 276 responses (overall response rate, 47.9%), 146 questionnaires were evaluable. LUTS had been experienced by 72 (49.3%) of the respondents, 17 (11.6%) had urge urinary incontinence, and 35 (24.0%) had stress urinary incontinence (SUI). The mean overall FSFI score was 22.4 ± 9.0. The mean FSFI score was not significantly different between women with LUTS and women without LUTS (23.2 ± 9.3 and 21.6 ± 8.8, respectively; P = 0.057). However, the mean FSFI score of women with SUI was significantly lower than that of women without it (P = 0.04). No other symptoms showed significant differences in FSFI scores.ConclusionsOur results suggest that sexual dysfunction is related to SUI.

Efficacy and safety of 3 day versus 7 day cefditoren pivoxil regimens for acute uncomplicated cystitis: multicentre, randomized, open-label trial

Background Fluoroquinolone-non-susceptible Escherichia coli isolated from patients with acute uncomplicated cystitis are a matter of increasing concern. Cefditoren pivoxil is an oral, &bgr;-lactamase-stable, extended-spectrum cephalosporin that is effective against fluoroquinolone-non-susceptible bacteria. Objectives To evaluate the clinical and microbiological efficacies of cefditoren pivoxil against acute uncomplicated cystitis and to determine the optimal duration of cefditoren pivoxil treatment. Methods We compared 3 and 7 day regimens of cefditoren pivoxil in a multicentre, randomized, open-label study. Results A total of 104 female patients with acute uncomplicated cystitis were enrolled and randomized into 3 day (n = 51) or 7 day (n = 53) treatment groups. At first visit, 94 bacterial strains were isolated from the 104 participants of which 81.7% (85/104) were E. coli. Clinical and microbiological efficacies were evaluated 5–9 days following administration of the final dose of cefditoren pivoxil. The clinical efficacies of the 3 and 7 day groups were 90.9% (40/44) and 93.2% (41/44), respectively (P = 1.000). The microbiological efficacies of the 3 and 7 day groups were 82.5% (33/40) and 90.2% (37/41), respectively (P = 0.349). There were no adverse events due to cefditoren pivoxil treatment, with the exception of a mild allergic reaction in one patient, after which the cefditoren pivoxil was exchanged for another antimicrobial. Conclusions Cefditoren pivoxil is safe and effective for uncomplicated cystitis, with no significant differences in clinical and microbiological efficacies between 3 and 7 day regimens.

Impact of selective media for detecting fluoroquinolone-insusceptible/extended-spectrum beta-lactamase-producing Escherichia coli before transrectal prostate biopsy

To investigate the prevalence of fluoroquinolone‐insusceptible and/or extended‐spectrum beta‐lactamase‐producing Escherichia coli colonizing in the male rectum before transrectal prostate biopsy.

The Effect of Hochuekkito on Female Stress Urinary Incontinence

女性腹圧性尿失禁患者に対して補中益気湯を4週間投与し，その臨床的有用性を検討した。女性腹圧性尿失禁患者13名に対し，食前に1日3回補中益気湯7.5gを4週間投与した。治療前，治療1カ月後に，VAS（visual analog scale），IQOL（Incontinence-QOL）による自覚症状の変化を観察し，また排尿日誌を用いて排尿回数，尿失禁回数の変化，パッドテストによる失禁量の変化，尿流測定による他覚的な排尿状態の変化の確認を行った。また投与終了時の患者の満足度も検討した。結果は有意差は認めなかったが，VAS，IQOLスコア，いずれも改善傾向であった。パッドテスト，失禁回数は減少傾向であった。排尿回数，最大尿流量は変化なく，患者満足度は高かった。BMI別で検討すると非肥満型では有意にVAS, IQOLの改善を認めた。補中益気湯は排尿状態に影響を及ぼさず，尿失禁の程度，証などを考慮すれば有効であることが示唆された。副作用として重篤なものは認めなかった。